HM
ALXN

HealthCor Management’s Alexion Pharmaceuticals ALXN Stock Holding History

HealthCor Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-61,330
Closed -$9.58M – 106
2020
Q4 		$9.58M Buy
+61,330
New +$7.88M 0.37% 43
2020
Q3 		– Sell
-666,510
Closed -$74.8M – 64
2020
Q2 		$74.8M Buy
666,510
+518,240
+350% +$55M 3.13% 12
2020
Q1 		$13.3M Buy
+148,270
New +$14.6M 0.57% 41
2018
Q3 		– Sell
-486,300
Closed -$60.4M – 59
2018
Q2 		$60.4M Buy
+486,300
New +$56.8M 1.92% 19
2017
Q2 		– Sell
-950,000
Closed -$115M – 50
2017
Q1 		$115M Buy
950,000
+688,860
+264% +$88.8M 5.28% 6
2016
Q4 		$31.9M Sell
261,140
-388,860
-60% -$47.6M 1.81% 20
2016
Q3 		$79.7M Buy
+650,000
New +$83.7M 4.85% 6
2016
Q2 		– Sell
-142,920
Closed -$19.9M – 52
2016
Q1 		$19.9M Buy
142,920
+83,030
+139% +$12.2M 1.13% 28
2015
Q4 		$11.4M Sell
59,890
-390,110
-87% -$68.1M 0.69% 29
2015
Q3 		$70.4M Buy
+450,000
New +$82.1M 3.96% 11
2015
Q1 		– Sell
-127,100
Closed -$23.5M – 82
2014
Q4 		$23.5M Sell
127,100
-22,900
-15% -$4.24M 1.31% 29
2014
Q3 		$24.9M Sell
150,000
-325,000
-68% -$53.4M 1.28% 28
2014
Q2 		$74.2M Buy
475,000
+457,700
+2,646% +$72.3M 3.72% 8
2014
Q1 		$2.63M Sell
17,300
-432,700
-96% -$68.8M 0.16% 53
2013
Q4 		$59.8M Buy
450,000
+50,000
+13% +$6M 3.63% 9
2013
Q3 		$46.5M Sell
400,000
-250,000
-38% -$27.4M 2.49% 15
2013
Q2 		$60M Buy
+650,000
New +$62.6M 3.63% 9

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HealthCor Management's ALXN Position: Q1 2021 in Review

HealthCor Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 61,330 shares — an estimated $9.58M sold.

HealthCor Management first reported a position in ALXN in Q2 2013 and held it in 17 quarters. The position peaked at $115M in Q1 2017. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • HealthCor Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • HealthCor Management sold 61,330 Alexion Pharmaceuticals shares in Q1 2021, an estimated $9.58M.
  • HealthCor Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • HealthCor Management's Alexion Pharmaceuticals position peaked at $115M in Q1 2017.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on HealthCor Management's 13F filing for Q1 2021, filed 17 May 2021.